Published in Cancer Weekly, May 27th, 2003
"EB1089, a novel vitamin D3 analog, has been shown to have cytotoxic and antiproliferative properties in a variety of malignant cells. However, its potential as a treatment for B-cell chronic lymphocytic leukemia (B-CLL) has not been evaluated.
"EB1089 induced apoptosis in all of the 102 B-CLL samples tested with a mean LD50 value (the concentration of EB1089 required to kill 50% of cells ± SD) of 21 x 10-8M ±1.4 x 10-8M," scientists writing in the journal Blood report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.